Regenerative medicine build-out

Stem Cells Translational Medicine

Volumn 4, Issue 12, 2015, Pages 1373-1379

  Terzic, Andre ^a   Pfenning, Michael A ^a   Gores, Gregory J ^a   Harper, C Michel ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HUMAN; NON PROFIT ORGANIZATION; PERSONALIZED MEDICINE; PROPHYLAXIS; REGENERATIVE MEDICINE; REIMBURSEMENT; TRANSPLANTATION; EDUCATION; MEDICAL EDUCATION; PROCEDURES; STANDARDS; TRANSLATIONAL RESEARCH; TRENDS;

CLINICAL TRIALS AS TOPIC; DELIVERY OF HEALTH CARE; EDUCATION, MEDICAL, CONTINUING; HUMANS; REGENERATIVE MEDICINE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84949649498     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0275     Document Type: Article

References (55)

1. Terzic A, Waldman S. Chronic diseases: The emerging pandemic. Clin Transl Sci 2011; 4:225–226.
2. World Health Organization. Global Status Report on Noncommunicable Diseases. Available at http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1. Accessed October 15, 2015.
3. Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics–2015 update: A report from the American Heart Association. Circulation 2015;131:e29–e322.
4. United Nations Population Fund. Ageing in the Twenty-First Century: A Celebration and a Challenge. Available at http://unfpa.org/ageingreport. Accessed October 15, 2015.
5. Terzic A, Nelson TJ. Regenerative medicine advancing health care 2020. J Am Coll Cardiol 2010;55:2254–2257.
6. U.S. Department of Health and Human Services. 2020:A New Vision–A Future for RegenerativeMedicine. Available at http://medicine.osu.edu/regenerativemedicine/documents/2020vision.pdf. Accessed October 15, 2015.
7. Terzic A, Nelson TJ. Regenerative medicine primer. Mayo Clin Proc 2013;88:766–775.
8. Fox IJ, Daley GQ, Goldman SA et al. Stem cell therapy: Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science 2014;345:1247391.
9. European Medicines Agency. First Stem-Cell Therapy Recommended for Approval in EU. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/12/news_detail_002239.jsp&mid=WC0b01ac058004d5c1. Accessed October 15, 2015.
10. Trounson A, McDonald C. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell 2015;17:11–22.
11. Atala A, Murphy S. Regenerative medicine. JAMA 2015;313:1413–1414.
12. Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol 2014;32: 773–785.
13. Nelson TJ, Behfar A, Terzic A. Strategies for therapeutic repair: The “R(3)” regenerative medicine paradigm. Clin Transl Sci 2008;1: 168–171.
14. Terzic A, Folmes CD, Martinez-Fernandez Aet al. Regenerative medicine:Onthe vanguard of health care. Mayo Clin Proc 2011;86: 600–602.
15. U.S. Department of Health&Human Services. Organ Procurement and Transplantation Network. Available at http://optn.transplant.hrsa.gov/. Accessed October 15, 2015.
16. McDonald-Hyman C, Turka LA, Blazar BR. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med 2015;7:280rv2.
17. Campbell A, Brieva T, Raviv L et al. Concise Review: Process development considerations for cell therapy. STEM CELLS TRANSLATIONAL MEDICINE 2015;4:1155–1163.
18. Mount NM, Ward SJ, Kefalas P et al. Cellbased therapy technology classifications and translational challenges. Philos Trans R Soc Lond B Biol Sci 2015;370:20150017.
19. Hunsberger J, Harrysson O, Shirwaiker R et al. Manufacturing road map for tissue engineering and regenerative medicine technologies. STEM CELLS TRANSLATIONAL MEDICINE 2015; 4:130–135.
20. Waldman SA, Terzic A. Managing the innovation supply chain to maximize personalized medicine. Clin Pharmacol Ther 2014;95: 113–118.
21. Terzic A, Harper CM Jr., Gores GJ et al. Regenerative medicine blueprint. Stem Cells Dev 2013;22(suppl 1):20–24.
22. Mayo Clinic. Center for Regenerative Medicine. Available at http://www.mayo.edu/research/centers-programs/center-regenerativemedicine. Accessed October 15, 2015.
23. Terzic A, Edwards BS, McKee KC et al. Regenerative medicine: A reality of stem cell technology. Minn Med 2011;94:44–47.
24. Mayo Clinic. Center for RegenerativeMedicine: Regenerative Medicine Biotrust. Available at http://www.mayo.edu/research/centersprograms/center-regenerative-medicine/about/shared-services/regenerative-medicine-biotrust. Accessed October 15, 2015.
25. Mayo Clinic. Center for Regenerative Medicine: Human Cellular Therapy Laboratory. Available at http://www.mayo.edu/research/centers-programs/center-regenerative-medicine/about/shared-services/human-cellular-therapylaboratory. Accessed October 15, 2015.
26. Dietz AB, Padley DJ, Gastineau DA. Infrastructure development for human cell therapy translation. Clin Pharmacol Ther 2007;82: 320–324.
27. Mayo Clinic. Advanced Product Incubator. Available at http://www.youtube.com/watch?v=7GrBJzjIhYE. Accessed October 15, 2015.
28. Mayo Clinic. Center for Regenerative Medicine: Clinical Trials. Available at http://www.mayo.edu/research/centers-programs/centerregenerative-medicine/patient-care/clinicaltrials. Accessed October 15, 2015.
29. Finnoff JT, Fowler SP, Lai JK et al. Treatment of chronic tendinopathy with ultrasound-guided needle tenotomy and platelet-rich plasma injection. PM R 2011; 3:900–911.
30. Gertz MA, Reeder CB, Kyle RA et al. Stem cell transplant for Waldenstr¨om macroglobulinemia: An underutilized technique. Bone Marrow Transplant 2012;47:1147–1153.
31. Penfield JD, Gorospe EC, Wang KK. Tissue-engineered cell sheets for stricture prevention: A new connection between endoscopy and regenerative medicine. Gastroenterology 2012;143:526–529.
32. Bartunek J, Behfar A, Dolatabadi D et al. Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013;61:2329–2338.
33. Evans CH. Advances in regenerative orthopedics. Mayo Clin Proc 2013;88:1323–1339.
34. Mao SA, Glorioso JM, Nyberg SL. Liver regeneration. Transl Res 2014;163:352–362.
35. Huebert RC, Rakela J. Cellular therapy for liver disease. Mayo Clin Proc 2014;89: 414–424.
36. Holditch SJ, Terzic A, Ikeda Y. Concise review: Pluripotent stem cell-based regenerative applications for failing b-cell function. STEM CELLS TRANSLATIONAL MEDICINE 2014;3:653–661.
37. Chim H, Amer H, Mardini S et al. Vascularized composite allotransplant in the realm of regenerative plastic surgery. MayoClin Proc 2014; 89:1009–1020.
38. Lott DG, Janus JR. Tissue engineering for otorhinolaryngology-head and neck surgery. Mayo Clin Proc 2014;89:1722–1733.
39. Behfar A, Crespo-Diaz R, Terzic A et al. Cell therapy for cardiac repair: Lessons from clinical trials. Nat Rev Cardiol 2014;11:232–246.
40. O’Brien T, Creane M, Windebank AJ et al. Translating stem cell research to the clinic: A primer on translational considerations for your first stem cell protocol. Stem Cell Res Ther 2015; 6:146.
41. Textor SC, Lerman LO. Paradigmshifts in atherosclerotic renovascular disease: Where are we now? J Am Soc Nephrol 2015;26: 2074–2080.
42. Wyles CC, Houdek MT, Crespo-Diaz RJ et al. Adipose-derived mesenchymal stem cells are phenotypically superior for regeneration in the setting of osteonecrosis of the femoral head. Clin Orthop Relat Res 2015; 473:3080–3090.
43. Burkhart HM, Qureshi MY, Peral SC et al. Regenerative therapy for hypoplastic left heart syndrome: First report of intraoperative intramyocardial injection of autologous umbilicalcord blood-derived cells. J Thorac Cardiovasc Surg 2015;149:e35–e37.
44. Matveyenko A, Vella A. Regenerative medicine in diabetes. Mayo Clin Proc 2015;90: 546–554.
45. Crespo-Diaz R, YamadaS, Bartunek J et al. Cardiopoietic index predicts heart repair fitness of patient-derived stem cells. Biomarkers Med 2015;9:639–649.
46. Prescott C, Polak DJ. The Delivery of Regenerative Medicines and Their Impact on Healthcare. Boca Raton, FL: CRC Press, 2011.
47. Innovation for Healthier Americans: Identifying Opportunities for Meaningful Reform to Our Nation’sMedical Product Discovery and Development. United States Senate: 2015 Report. Available at http://www.help.senate.gov/imo/media/Innovation_for_Healthier_Americans.pdf. Accessed October 15, 2015.
48. Trounson A, DeWitt ND, Feigal EG. The Alpha Stem Cell Clinic: A model for evaluating and delivering stem cell-based therapies. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:9–14.
49. French A, Suh JY, Suh CY et al. Global strategic partnerships in regenerative medicine. Trends Biotechnol 2014;32:436–440.
50. Fujita Y, Kawamoto A. Regenerativemedicine legislation in Japan for fast provision of cell therapy products. Clin Pharmacol Ther. [Epub ahead of print].
51. Cortese DA. A health care encounter of the 21st century. JAMA 2013;310:1937–1938.
52. Dimmeler S, Ding S, Rando TA et al. Translational strategies and challenges in regenerative medicine. Nat Med 2014;20:814–821.
53. Waldman SA, Terzic A. Knowledge cycle transforms therapeutic innovation. Clin Pharmacol Ther 2012;91:3–8.
54. Terzic A, Behfar A. Regenerative heart failure therapy headed for optimization. Eur Heart J 2014;35:1231–1234.
55. Behfar A, Terzic A. Stem cells versus senescence: The yin and yang of cardiac health. J Am Coll Cardiol 2015;65:148–150.